Melanie Graham from Dana-Farber contacted me last week to let me know about an article featuring Dr. Anderson, Dr. Richardson and their colleague, Dr. Nikhil Munshi. Myeloma geeks like me know that Ken Anderson and Paul Richardson are two of the most renowned myeloma specialists in the world. If they made sets of baseball cards
I had the opportunity to participate in and listen to two different educational programs this week. Monday I volunteered to host and speak to a group fellow Moffitt Cancer Center patients, caregivers and family members. Over 100 attended a three part educational event. Neurosurgeon Dr. Nam Tran spoke to the group about bone disease treatment
Wednesday I asked long-lived myeloma survivors to email me with advice for newly diagnosed patients. I have received a number of inspiring responses so far. There have also been some heartwarming and informative comments following that post. Do you take the time to view reader comments? I know many of you often don't. But in
Enough about me! Here's an excerpt I saved from earlier this week on OncLive.com, featuring an interview with Dana-Farber's Dr. Ken Anderson: Overcoming Genetic Transformation in Multiple Myeloma Bonnie Gillis - OriginallyPublished Online: Tuesday, November 6, 2012 The goal in treating newly diagnosed multiple myeloma is to achieve deep remission and prevent relapse, Kenneth C.
Our old friend, Dr. Kenneth Anderson, is at it again! Check-out excerpts from Dana Farber's website about an experimental anti-myeloma molecule, P5091: Molecule shows effectiveness against drug-resistant myeloma Posted On: September 10, 2012 BOSTON––A molecule that targets the cell's machinery for breaking down unneeded proteins can kill multiple myeloma cancer cells resistant to the frontline
I featured a number of links to important new therapy related news from ASH over the past few days at MyelomaNews.com. One of the links is to a Medscape Today article about vorinostat (trade name Zolinza), which includes comments from Dr. Noopur Raje, who I worked with a few weeks back in Cambridge. She is
Dana-Farber's Dr. Kenneth Anderson recently released a video series about multiple myeloma on YouTube. All are worthwhile. But make sure to play the video at the top of the page, "Promising areas of research in multiple myeloma." Dr. Anderson opens the clip by saying that there has been a lot of progress in treating multiple
Here is a press release, posted on the Drug Discovery & Development Website from Merck Pharmaceuticals about the new, experimental multiple myeloma drug, Vorinostat:Board Recommends Continuation of Phase IIb Study of VorinostatDrug Discovery & Development - February 15, 2010Merck & Co., Inc. announced that an independent Data Safety and Monitoring Board recommended the continuation of
While I was in New Orleans at AHS, I had a chance to meet Dr. Kenneth Anderson, a myeloma specialist with Dana-Farber in Boston and Harvard Medical School. Dr. Anderson is a small man--quiet and reserved. So if he gets excited about something, you notice! So as I passed the large Merck Pharmaceutical exhibit in
Yesterday I promised more information about vorinostat. Here is what ChemoCare.Com has to say about the drug:How Vorinostat Works: Cancerous tumors are characterized by cell division, which is no longer controlled as it is in normal tissue. "Normal" cells stop dividing when they come into contact with like cells, a mechanism known as contact inhibition.
Here is a clinical summary about the new myeloma drug I wrote about last night, perifosine, from a Website named "drugdevelopment-technology.com:"KRX-0401 (perifosine) is a potential oral anti-cancer agent that suppresses the pathways associated with the programmed growth, death, differentiation and survival of cells. Developed by Keryx, the drug is most effective in modulating Akt, as
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Here is info about a newly organized Phase 3 study combining perifosine with Velcade:NEW YORK, Dec 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. The trial,
I'm back. The oysters were hot and tender. What a fun place Mother's Restaurant is! It was recommended to me on my flight here from Tampa by a interesting, pleasant woman, Julie Barreda, who runs a culinary tour company. Doesn't that sound like a great gig, leading fun eating tours to places like New Orleans,